Minocycline protects basal forebrain cholinergic neurons from mu p75-saporin immunotoxic lesioning.
Two prominent characteristics of Alzheimer's disease are basal forebrain cholinergic degeneration and neuroinflammation characterized by glial activation and the release of pro-inflammatory cytokines. Mu p75- saporin (SAP) is a novel immunotoxin that mimics the selective loss of basal forebrain cholinergic neurons and induces cognitive impairment in mice. We report that cholinergic cell loss in the medial septal nucleus and ventral diagonal band after i.c.v. injection of mu p75-SAP is accompanied by simultaneous activation of microglia and astrocytes in the basal forebrain region as well as significant memory loss. Consistent with a role of glial cells in the pathology of Alzheimer's disease, minocycline, a second-generation tetracycline with known anti-inflammatory and neuroprotective properties, attenuated mu p75-SAP-induced cholinergic cell loss, glial activation and transcription of downstream pro-inflammatory mediators. In addition to neuroprotection, minocycline treatment mitigated the cognitive impairment that appears to be a functional consequence of mu p75-SAP lesioning. The current study demonstrates that glial-related inflammation plays a significant role in the selective neurotoxicity of mu p75-SAP, and suggests that minocycline may provide a viable therapeutic option for degenerating cholinergic systems.
Hunter
Christopher L
CL
Department of Physiology and Neuroscience and the Center on Aging, Medical University of South Carolina, 26 Bee street, Charleston, SC 29425, USA.
Quintero
E Matthew
EM
Gilstrap
Lindsay
L
Bhat
Narayan R
NR
Granholm
Ann-Charlotte
AC
D000544:Alzheimer Disease / Q000517:prevention & control; D000818:Animals; D001253:Astrocytes / Q000187:drug effects / Q000378:metabolism; D002799:Cholinergic Fibers / Q000187:drug effects / Q000473:pathology*; D004195:Disease Models, Animal; D015870:Gene Expression / Q000187:drug effects; D007150:Immunohistochemistry; D000922:Immunotoxins / Q000008:administration & dosage / Q000633:toxicity*; D007276:Injections, Intraventricular; D007375:Interleukin-1 / Q000096:biosynthesis / Q000235:genetics; D008262:Macrophage Activation / Q000187:drug effects; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D008569:Memory Disorders / Q000473:pathology / Q000517:prevention & control; D051379:Mice; D008810:Mice, Inbred C57BL; D017628:Microglia / Q000187:drug effects / Q000378:metabolism; D008911:Minocycline / Q000494:pharmacology*; D009699:N-Glycosyl Hydrolases / Q000008:administration & dosage / Q000633:toxicity*; D009410:Nerve Degeneration / Q000473:pathology / Q000517:prevention & control; D018696:Neuroprotective Agents / Q000494:pharmacology*; D010940:Plant Proteins / Q000008:administration & dosage / Q000633:toxicity*; D016548:Prosencephalon / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D054789:Ribosome Inactivating Proteins, Type 1; D000076985:Saporins; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis / Q000235:genetics
D000922:Immunotoxins; D007375:Interleukin-1; D018696:Neuroprotective Agents; D010940:Plant Proteins; D054789:Ribosome Inactivating Proteins, Type 1; D014409:Tumor Necrosis Factor-alpha; D009699:N-Glycosyl Hydrolases; D000076985:Saporins; D008911:Minocycline